在3T场强下使用暗血、脂肪抑制、Dixon不平衡T1弛豫增强稳态MRI提高脑肿瘤可见性
该回顾性研究纳入47例因脑肿瘤指征行3T增强脑MRI的成人患者,对比Dixon uT1RESS与MPRAGE序列。结果显示两者图像质量评分无显著差异,但Dixon uT1RESS的运动伪影稍差;Dixon uT1RESS显著提高肿瘤-脑对比度(约2.5倍),在转移性疾病患者中平均24.7%的患者检出MPRAGE漏掉的至少1个强化病灶,且未漏掉MPRAGE显示的任何病灶。作者认为Dixon uT1RESS可能成为颅内肿瘤增强后评估的有用辅助或替代技术。
要点
- Dixon uT1RESS在3T增强脑MRI中肿瘤-脑对比度显著高于MPRAGE,约提高2.5倍。
- 转移性疾病患者中,Dixon uT1RESS平均在24.7%的患者检出MPRAGE漏掉的至少1个强化脑病灶。
- Dixon uT1RESS未漏掉MPRAGE显示的任何病灶,并在少数患者中更好地检出血管和硬脑膜侵犯。
核心结论
- 在3T场强下,Dixon uT1RESS较MPRAGE显著提高脑肿瘤可见性,病灶-背景对比度约提高2.5倍,不受序列采集顺序影响;在脑转移瘤、硬脑膜或血管侵犯检测方面优于MPRAGE;作者认为Dixon uT1RESS可能成为颅内肿瘤增强后评估的有用辅助或替代技术。
研究设计与样本
- 回顾性研究,经医院机构审查委员会批准,纳入47例因脑肿瘤指征行MRI扫描的成人患者,在3T场强下同时使用MPRAGE和Dixon uT1RESS行增强脑MRI;约半数受试者立即在MPRAGE后采集Dixon uT1RESS,另一半立即在MPRAGE前采集,以控制扫描过程中对比剂洗脱的影响;由3名阅片者评分图像质量、伪影和病灶检测,并通过感兴趣区测量计算病灶表观信噪比和病灶-背景Weber对比度。
关键影像表现/征象
- Dixon uT1RESS与MPRAGE的图像质量评分无显著差异,但Dixon uT1RESS的运动伪影稍差。
- Dixon uT1RESS的平均病灶表观信噪比为199.31 ± 99.05,MPRAGE为203.81 ± 110.23,两者无显著差异。
- Dixon uT1RESS在MPRAGE前采集时肿瘤-脑对比度为1.60 ± 1.18,MPRAGE为0.61 ± 0.47;Dixon uT1RESS在MPRAGE后采集时肿瘤-脑对比度为1.94 ± 0.97,MPRAGE为0.82 ± 0.55。
- 在转移性疾病患者中,Dixon uT1RESS平均在24.7%的患者检出至少1个MPRAGE漏掉的强化脑病灶,而Dixon uT1RESS未漏掉MPRAGE显示的任何病灶。
- Dixon uT1RESS在少数患者中更好地检出血管和硬脑膜侵犯。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Contrast-enhanced magnetic resonance imaging (MRI) is the cornerstone for brain tumor diagnosis and treatment planning. We have developed a novel dual-echo volumetric dark blood pulse sequence called Dixon unbalanced T1 relaxation-enhanced steady-state (uT 1 RESS) that improves the visibility of contrast-enhancing lesions while suppressing the tissue signals from blood vessels and fat. The purpose of this study was to test the hypothesis that Dixon uT 1 RESS would significantly improve the conspicuity of brain tumors compared with magnetization-prepared rapid gradient echo (MPRAGE), as well as to determine potential limitations of the technique.
MATERIALS AND METHODS: This retrospective study was approved by the hospital institutional review board. Forty-seven adult patients undergoing an MRI scan for a brain tumor indication were included. Contrast-enhanced MRI of the brain was performed at 3 T using both MPRAGE and Dixon uT 1 RESS. To control for any impact of contrast agent washout during the scan procedure, Dixon uT 1 RESS was acquired in approximately half the subjects immediately after MPRAGE, and in the other half immediately before MPRAGE. Image quality, artifacts, and lesion detection were scored by 3 readers, whereas lesion apparent signal-to-noise ratio and lesion-to-background Weber contrast were calculated from region-of-interest measurements.
RESULTS: Image quality was not rated significantly different between MPRAGE and Dixon uT 1 RESS, whereas motion artifacts were slightly worse with Dixon uT 1 RESS. Comparing Dixon uT 1 RESS with MPRAGE, the respective values for mean lesion apparent signal-to-noise ratio were not significantly different (199.31 ± 99.05 vs 203.81 ± 110.23). Compared with MPRAGE, Dixon uT 1 RESS significantly increased the tumor-to-brain contrast (1.60 ± 1.18 vs 0.61 ± 0.47 when Dixon uT1RESS was acquired before MPRAGE and 1.94 ± 0.97 vs 0.82 ± 0.55 when Dixon uT 1 RESS was acquired after MPRAGE). In patients with metastatic disease, Dixon uT 1 RESS detected at least 1 enhancing brain lesion that was missed by MPRAGE on average in 24.7% of patients, whereas Dixon uT 1 RESS did not miss any lesions that were demonstrated by MPRAGE. Dixon uT 1 RESS better detected vascular and dural invasion in a small number of patients.
CONCLUSIONS: In conclusion, brain tumors were significantly more conspicuous at 3 T using Dixon uT 1 RESS compared with MPRAGE, with an approximately 2.5-fold improvement in lesion-to-background contrast irrespective of sequence order. It outperformed MPRAGE for the detection of brain metastases, dural or vascular involvement. These results suggest that Dixon uT 1 RESS could prove to be a useful adjunct or alternative to existing neuroimaging techniques for the postcontrast evaluation of intracranial tumors.
引用
- Edelman RR, Walker M, Ankenbrandt WJ, et al. Improved Brain Tumor Conspicuity at 3 T Using Dark Blood, Fat-Suppressed, Dixon Unbalanced T1 Relaxation-Enhanced Steady-State MRI. Invest Radiol. 2023. PMID: 36822675. doi:10.1097/RLI.0000000000000964
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。